Chemotherapy · 2012 · 57 citations · 39 references
MedicineOncologyPharmacologyCancer PharmacologyChemotherapyMedical OncologyCytotoxic ChemotherapyLung CancerLung Cancer PharmacotherapyPharmacodynamics Of Anticancer AgentsPharmacodynamics Of Anticancer DrugsTargeted Cancer TherapyAntimitotic ActivityAntimitotic ChemotherapyAntimitotic DrugsAntimitotic TreatmentsChemotherapy Dose-limiting ToxicityExpansion Cohort DesignNon-small Cell Lung Cancer TherapyNon-small Cell Lung Cancer Treatment
BACKGROUND: ABT-751 is a novel antimitotic agent that exerted cytotoxic effects in preclinical studies. Carboplatin has efficacy in treating advanced non-small cell lung cancer (NSCLC) in combination with other drugs. METHODS: Lung cancer cell lines were treated with ABT-751 and/or carboplatin to investigate their impact on cell growth. A phase I study with an expansion cohort was conducted in previously treated NSCLC patients. The primary objective was the maximum tolerated dose (MTD); secondary objectives were objective response rates, median survival, time to tumor progression, dose-limiting toxicities (DLTs), and pharmacodynamic evaluation of buccal swabs. RESULTS: Combining ABT-751 with carboplatin significantly reduced growth and induced apoptosis of lung cancer cell lines. Twenty advanced NSCLC patients were enrolled. MTD was ABT-751 125 mg orally twice daily for 7 days with carboplatin AUC 6. DLTs included fatigue, ileus, neutropenia and pneumonitis. Two patients had confirmed partial responses. Median overall survival was 11.7 months (95% CI 5.9-27.0). Time to tumor progression was 2.8 months (95% CI 2.0-2.7). Four of 6 patients showed decreased cyclin D1 protein in posttreatment versus pretreatment buccal swabs. CONCLUSION: Combining ABT-751 with carboplatin suppressed growth of lung cancer cell lines and had modest clinical antitumor activity in advanced NSCLC previously treated predominantly with carboplatin. Further studies of this combination are not recommended while investigations of biomarkers in different patient populations, alternative schedules and combinations may be pursued.
39
The National Comprehensive Cancer Network
William T. McGivney · Cancer · 1998 · 16.9K citations
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Alan Sandler, Robert J. Gray, Michael C. Perry et al. · New England Journal of Medicine · 2006 · 5.8K citations · Full text
Medicine, Oncology, Pharmacology +13
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Frances A. Shepherd, José Rodrigues Pereira, Tudor–Eliade Ciuleanu et al. · New England Journal of Medicine · 2005 · 5.5K citations · Full text
Medicine, Oncology, Pharmacology +15
Nasser H. Hanna, Frances A. Shepherd, Frank V. Fossella et al. · Journal of Clinical Oncology · 2004 · 2.4K citations · Full text
Medicine, Oncology, Pharmacology +15